<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707122</url>
  </required_header>
  <id_info>
    <org_study_id>ALBIOS</org_study_id>
    <nct_id>NCT00707122</nct_id>
  </id_info>
  <brief_title>Volume Replacement With Albumin in Severe Sepsis</brief_title>
  <acronym>ALBIOS</acronym>
  <official_title>Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND The association between mortality and hypoalbuminemia has been observed in several&#xD;
      diseases. Nonetheless, the efficacy of albumin on survival in critically ill patients is&#xD;
      controversial. Several meta-analyses have reported either negative, neutral, or beneficial&#xD;
      effects of albumin administration. To clarify this controversy, a large multicenter&#xD;
      prospective study has been performed, comparing the effects of 4% albumin vs. saline for&#xD;
      volume replacement in critically ill patients. Although no difference in the overall&#xD;
      mortality has been observed, a predefined subgroup analysis has shown a trend of longer&#xD;
      survival in septic patients treated with albumin. As fluid replacement has been shown to be&#xD;
      critical in sepsis, and based on both its primary (oncotic) and secondary properties&#xD;
      (anti-inflammatory), it is conceivable that the use of albumin for volume replacement and for&#xD;
      treating hypoalbuminemia may have a beneficial effects on survival of septic patients.&#xD;
&#xD;
      OBJECTIVES Primary objective: to verify whether volume replacement with albumin (treated&#xD;
      group) and its maintenance within plasmatic physiologic range (equal or above 30 g/l)&#xD;
      improves survival of patients with severe sepsis of septic shock, as compared to crystalloids&#xD;
      (control group). Secondary objectives: to verify the differences in organ dysfunctions,&#xD;
      hospital and intensive care unit (ICU) length of stay between the treated and control group.&#xD;
&#xD;
      METHODS About 1350 patients with severe sepsis or septic shock will be randomized to receive&#xD;
      either albumin or crystalloids as fluid therapy. Volume replacement will be performed for&#xD;
      both groups according to the early-goal directed therapy. Treated group will receive 60 gr&#xD;
      albumin infusion after randomization, and 40-60 gr albumin daily infusion to maintain serum&#xD;
      album level equal or above 30 g/l. Control group will receive crystalloids for the entire&#xD;
      study; albumin administration will be allowed only when daily serum albumin level will be&#xD;
      lower than 15 g/l. Patients will be treated until the 28th day after randomization or until&#xD;
      ICU discharge, whichever comes first.&#xD;
&#xD;
      EXPECTED RESULTS Primary outcomes: absolute risk reduction of overall mortality of 7.5% at&#xD;
      28th day, with a further control at 90th day, following randomization. Secondary outcomes:&#xD;
      reduction of number and severity of organ dysfunctions (as assessed by the Sequential Organ&#xD;
      Failure Assessment score), reduction of ICU and hospital length of stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND RATIONALE The association between mortality and hypoalbuminemia has been&#xD;
      documented in several diseases, including liver cirrhosis, nephrosic syndrome, and others.&#xD;
      Being responsible for about 80% of the oncotic power of plasma protein in humans, albumin is&#xD;
      a key factor in regulating the fluid exchange between interstitial and intravascular spaces,&#xD;
      thereby extensively affecting hemodynamics. Besides its oncotic properties, albumin presents&#xD;
      other characteristics potentially important in critically ill patients: 1 - a binding&#xD;
      capacity for several physiological molecules and drugs, 2 - a scavenging action on oxygen&#xD;
      free radicals, 3 - a modulating activity on nitric oxide (NO) metabolism, and 4 - a buffer&#xD;
      power for the acid-base equilibrium.&#xD;
&#xD;
      Regardless its theoretical usefulness, the efficacy of albumin administration on survival in&#xD;
      critically ill patients is controversial. The critical review published by the Cochrane&#xD;
      Albumin Reviewers in 1998, including 30 clinical studies, has shown an increased mortality of&#xD;
      critically ill patients treated with albumin. A further meta-analysis performed in 2001,&#xD;
      including 55 clinical trials, has concluded that albumin administration is safe although with&#xD;
      no effects on survival. In a more recent meta-analysis, including 90 cohort studies, and,&#xD;
      separately, 9 prospective controlled trials on correcting albumin level, hypoalbuminemia has&#xD;
      been shown to be a negative prognostic factor in terms of mortality, morbidity and length of&#xD;
      stay, with a dose-dependent effect. In particular, each 10-g/l decline in plasmatic albumin&#xD;
      level has been observed to significantly increase the odds of mortality by 137%. Moreover,&#xD;
      the analysis performed within 9 controlled trials has suggested that complication rates may&#xD;
      be reduced when plasmatic albumin concentration is maintained above 30 g/l. To clarify these&#xD;
      controversial findings, a multicenter double-blinded randomized prospective study has been&#xD;
      performed in about 7000 critically ill patients, comparing the effects of 4% albumin vs.&#xD;
      saline infusion for volume replacement. Although no difference in the overall mortality has&#xD;
      been observed, a predefined subgroup analysis has shown a trend of improvement in survival in&#xD;
      patients treated with albumin affected by severe sepsis (p=0.09). In contrast, a trend&#xD;
      towards a worse outcome in patients treated with albumin has been observed in the subgroup of&#xD;
      patients with trauma (p=0.06), likely due to the higher number of patients with trauma&#xD;
      associated to brain injury who did not survive in the albumin-treated group. These findings,&#xD;
      therefore, highlight the importance of characterizing different types of critically ill&#xD;
      patients who may benefit or not from albumin administration.&#xD;
&#xD;
      More recently, a further prospective, randomized controlled study has shown, in a series of&#xD;
      100 patients admitted to an intensive care unit (ICU), a significant reduction of organ&#xD;
      dysfunction, as detected by the Sequential Organ Failure Assessment (SOFA) score, after&#xD;
      correction of hypoalbuminemia with albumin administration.&#xD;
&#xD;
      In parallel to the investigations on the role of albumin in critically ill patients, an&#xD;
      increasing interest has been focused on the timing and the hemodynamic target of volume&#xD;
      replacement in septic patients. In particular, a recent randomized controlled study performed&#xD;
      in patients with sepsis has shown a better survival in the group of patients in which fluid&#xD;
      replacement has been obtained as early as possible according to predefined hemodynamic&#xD;
      targets (&quot;early goal-directed therapy&quot;), as compared to the control group. Focusing our&#xD;
      attention on septic patients, we can, therefore, conclude that: a - the early-goal directed&#xD;
      volume replacement improves survival, and, b - the &quot;type&quot; of volume replacement may have a&#xD;
      further effect on survival. In fact, volume replacement with the use of saline requires a&#xD;
      greater amount of fluid and may lead to metabolic acidosis. On the other hand, volume&#xD;
      replacement with the use of hydroxyethyl starch is potentially harmful. Volume replacement&#xD;
      with the use of albumin does not involve any known risk and may also be beneficial in septic&#xD;
      patients.&#xD;
&#xD;
      The current study aims to verify whether volume replacement with the use of albumin and its&#xD;
      maintenance within plasmatic physiologic ranges may have beneficial effects in terms of&#xD;
      mortality, morbidity and length of stay in patients with severe sepsis or septic shock, as&#xD;
      compared to a standard volume replacement with the use of crystalloids. For this purpose, and&#xD;
      to overcome the possible biases explained above, the study design will include two different&#xD;
      and important aspects: 1 - for both arms of the study population, i.e., patients treated with&#xD;
      albumin or with crystalloids, volume replacement will be performed according to the&#xD;
      &quot;early-goal directed therapy&quot;; 2 - during volume replacement, and for the following days of&#xD;
      treatment until the 28th day of admission in ICU (or until the day of ICU discharge,&#xD;
      whichever comes first), serum albumin level will be monitored and kept equal or above a level&#xD;
      of 30 g/l only in the albumin treated group. Such a study design will have several&#xD;
      advantages. In particular, the introduction of the &quot;early-goal directed therapy&quot; both in&#xD;
      patients treated with albumin or crystalloids, with the use of pre-defined hemodynamic&#xD;
      targets, will standardize and optimize volume replacement for all the septic patients&#xD;
      according to the standard care at the moment suggested worldwide. Moreover, it will allow us&#xD;
      to specifically observe the direct effects of albumin administration per se and the&#xD;
      maintenance of its serum level within normal range. In fact, besides its oncotic properties,&#xD;
      it is conceivable that the physiological characteristics of albumin potentially important in&#xD;
      septic patients (such as NO modulation, free oxygen radical scavenging, and acid-base&#xD;
      homeostasis) may have a possible benefit on survival, especially after the early&#xD;
      resuscitation phase.&#xD;
&#xD;
      Under this perspective, in the attempt to elucidate the possible mechanisms by which the use&#xD;
      of albumin for volume replacement may be beneficial in patients with sepsis, we will plan to&#xD;
      create a centralized blood bank including blood samples sequentially withdrawn from patients&#xD;
      included in the study population to evaluate the effects of albumin on biological markers.&#xD;
      Albumin, in fact, may have important effects on reducing the overall systemic inflammation&#xD;
      ongoing in septic patients, thereby explaining a possible direct benefit of its&#xD;
      administration. For this purpose, we plan to involve a sub-group of 50 participating ICUs&#xD;
      enrolling about 700 patients, in which three serum samples will be withdrawn (at day 1, day 2&#xD;
      and day 7 after the enrollment) and stored in the bank.&#xD;
&#xD;
      PRIMARY OBJECTIVE To verify the hypothesis that volume replacement with albumin and its&#xD;
      maintenance within predefined plasmatic physiologic range (equal to or greater than 30 g/l)&#xD;
      improves survival of patients with severe sepsis or septic shock, as compared to a volume&#xD;
      replacement with the use of crystalloids. Survival will be measured until the 28th and 90th&#xD;
      day after enrollment.&#xD;
&#xD;
      SECONDARY OBJECTIVES&#xD;
&#xD;
      To verify the hypothesis that volume replacement with albumin and its maintenance within&#xD;
      predefined plasmatic physiologic range (equal to or greater than 30 g/l) reduces:&#xD;
&#xD;
        1. The numbers and the severity of organ dysfunction, as detected by the SOFA score&#xD;
&#xD;
        2. The hospital length of stay&#xD;
&#xD;
        3. ICU length of stay&#xD;
&#xD;
      SUB-STUDY To understand the possible mechanisms by which albumin administration and the&#xD;
      maintenance of its serum level equal or above 30 g/l might be potentially beneficial, as&#xD;
      compared to crystalloids, in patients with severe sepsis of septic shock, with a particular&#xD;
      regard to the inflammatory process characterizing this category of patients. For this&#xD;
      purpose, by creating a blood bank of sequential plasmatic samples of patients included in the&#xD;
      study, we aim to detect any possible difference between the plasmatic levels of biologic&#xD;
      markers of systemic inflammation.&#xD;
&#xD;
      STUDY POPULATION Every patient admitted to ICU throughout the study period will be screened&#xD;
      for eligibility. International standard criteria will be applied to identify patients with&#xD;
      severe sepsis or septic shock. According to the &quot;early-goal directed therapy&quot;, after the&#xD;
      diagnosis, patients will receive arterial and central venous catheterization, if not yet&#xD;
      performed. In addition to volume replacement and albumin administration scheduled for the&#xD;
      study, patients will be clinically treated according to the criteria of the treating&#xD;
      physician. We will strongly encourage the participating Units to follow the guidelines of&#xD;
      treating sepsis published by the Surviving Sepsis Campaign. In addition to study fluids,&#xD;
      physicians will be allowed to administer blood products, and either enteral or parenteral&#xD;
      nutrition, when needed. Screening for patient eligibility will begin either at ICU entry or&#xD;
      at the emergency room, wherever the diagnosis of severe sepsis or septic shock will be made.&#xD;
      After assessing for eligibility, each Unit will notify the Coordinating Center to be assigned&#xD;
      to either the treatment or the control arm. The entire study will then be conducted in ICU&#xD;
      until the 28th day of admission or until ICU discharge, whichever comes first.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Patients with severe sepsis or septic shock, if each one of the following criteria is&#xD;
      satisfied:&#xD;
&#xD;
        1. Proved or suspected infection in at least one site:&#xD;
&#xD;
             1. lung&#xD;
&#xD;
             2. abdomen&#xD;
&#xD;
             3. genito-urinary tract&#xD;
&#xD;
             4. other (blood, skin and soft tissue, central nervous system, bones and joints,&#xD;
                cardiac system, catheter-related infection, other)&#xD;
&#xD;
        2. Two or more of the following:&#xD;
&#xD;
             1. a core temperature ≥ 38° C o ≤ 36° C;&#xD;
&#xD;
             2. a heart rate ≥ 90 beats/min;&#xD;
&#xD;
             3. a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of mechanical&#xD;
                ventilation for an acute process;&#xD;
&#xD;
             4. a white blood cell count ≥ 12000/ml or ≤ 4000/ml or immature neutrophils &gt; 10%.&#xD;
&#xD;
        3. Presence of at least a severe organ dysfunction, as measured by the modified Sequential&#xD;
           Organ Failure Assessment (SOFA) score:&#xD;
&#xD;
             1. respiratory score &gt; 1;&#xD;
&#xD;
             2. hematologic score &gt; 1;&#xD;
&#xD;
             3. hepatic score &gt; 1;&#xD;
&#xD;
             4. cardiovascular score equal to 1, 3 or 4;&#xD;
&#xD;
             5. renal score &gt; 1.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Age below 18 years&#xD;
&#xD;
        2. Terminal state&#xD;
&#xD;
        3. Known adverse reaction to albumin administration&#xD;
&#xD;
        4. Severe sepsis or septic shock in patients after proved or suspected head injury,&#xD;
           clinically active&#xD;
&#xD;
        5. Congestive heart failure (NYHA score III and IV)&#xD;
&#xD;
        6. Pathological conditions in which albumin administration is clinically indicated (hepatic&#xD;
           cirrhosis with ascites, intestinal malabsorption syndrome, nephritic syndrome, burns)&#xD;
&#xD;
        7. More than 24 hours since inclusion criteria were met&#xD;
&#xD;
        8. Religious objection to the administration of human blood products&#xD;
&#xD;
        9. Inclusion in other experimental study&#xD;
&#xD;
      INTERVENTION/EXPOSURE After its approval by the Ethical Committee, the study will be&#xD;
      activated as follows: 1- screening for eligibility, 2- informed consent, 3- inclusion in the&#xD;
      study via centralized randomization.&#xD;
&#xD;
      Volume replacement will be performed in both the treated and the control group according to&#xD;
      the &quot;early-goal directed therapy&quot;. In the treated group, after randomization and&#xD;
      simultaneously to volume replacement, 300 ml of 20% of albumin solution (total amount of 60&#xD;
      gr) will be infused over a period of 3 hours. From day 2 to day 28 (or until ICU discharge,&#xD;
      whichever comes first), fluid will be administered as follows:&#xD;
&#xD;
        1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum&#xD;
           concentration equal or above 30 g/l (8). In particular, after the daily determination of&#xD;
           its serum level:&#xD;
&#xD;
             1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr)&#xD;
                will be infused;&#xD;
&#xD;
             2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution&#xD;
                (total amount of 40 gr) will be infused;&#xD;
&#xD;
             3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions&#xD;
                will be infused over a period of 3 hours. Further infusion of crystalloids will be&#xD;
                allowed, when necessary, according to the clinical judgment. No infusion of&#xD;
                colloids, other than albumin, will be admitted.&#xD;
&#xD;
        2. control group: crystalloids infusion will be allowed whenever necessary on a clinical&#xD;
           basis. Albumin administration will be restricted to emergency use, as clinically judged&#xD;
           and documented according to the standard criteria of each participating unit. No other&#xD;
           colloids will be allowed.&#xD;
&#xD;
      OUTCOMES&#xD;
&#xD;
      Primary outcomes:&#xD;
&#xD;
      1. Absolute risk reduction of overall mortality of 7.5% at the 28th, with a further control&#xD;
      at 90th day, after randomization&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        1. Reduction of the number and the severity of organ dysfunction (as recorded by the SOFA&#xD;
           score)&#xD;
&#xD;
        2. Reduction of the length of stay in ICU&#xD;
&#xD;
        3. Reduction of the hospital length of stay&#xD;
&#xD;
      INFORMATION RETRIEVAL Blood samples for the biohumoral sub-study will be obtained on day 1, 2&#xD;
      and 7 following randomization, to be stored in the central blood bank for subsequent&#xD;
      analysis.&#xD;
&#xD;
      Baseline data foreseen for the inclusion procedure, including source of ICU admission, by&#xD;
      definition will be collected and validated centrally in coincidence with the randomization.&#xD;
      As soon as each case is concluded, the original copy of the self-copying Clinical Research&#xD;
      Form (CRF) is sent to the Coordinating Center, for quality control of clinical data, which is&#xD;
      the prerequisite for the formal checks and input into the study database. A copy of the&#xD;
      original paper CRF will remain at the Clinical Center, to comply with all legal and&#xD;
      regulatory requirements foreseen in the International Conference on Harmonization-Good&#xD;
      Clinical Practice (ICH-GCP) rules.&#xD;
&#xD;
      The following clinical variables, usually included in the standard care of septic patients,&#xD;
      will be collected: hemodynamics (HR, MAP, CVP, urinary output; type and dosage of vasoactive&#xD;
      agents), blood gas analysis values, body temperature, laboratory tests (serum level of urea,&#xD;
      creatinine, potassium, sodium, bilirubin, albumin; hemoglobin level, hematocrit, WBC count,&#xD;
      glycemia, platelet count, prothrombin and activated partial thromboplastin time), Glasgow&#xD;
      Coma Scale, SOFA score, infection and antibiotic treatment, amount and type of fluids&#xD;
      administered within the previous 24 hours (or prior randomization), net positive fluid&#xD;
      balance, ventilatory setting, adverse or specific clinical event. Variables will be&#xD;
      retrieved:&#xD;
&#xD;
        1. At baseline (within 6 hours from randomization)&#xD;
&#xD;
        2. On a daily basis, from day 1 to day 28 after randomization or until ICU discharge&#xD;
           (whichever comes first)&#xD;
&#xD;
      We will apply the following indicators:&#xD;
&#xD;
        1. Simplified Acute Physiologic Score (SAPS II), to assess the severity of systemic disease&#xD;
           at study entry.&#xD;
&#xD;
        2. Sequential Organ Failure Assessment (SOFA) score, to monitor organ failure at study&#xD;
           entry and during its course.&#xD;
&#xD;
      The study will not be conducted in a blinded fashion, as in that case it would need a&#xD;
      specifically designed setting for fluid administration, excessively expensive, and, de facto,&#xD;
      unpractical (in terms of workload and organization). The use of the &quot;early-goal directed&#xD;
      therapy&quot; for hemodynamic treatment, with the use of predefined hemodynamic targets, should&#xD;
      assure the approach to hemodynamic optimization independently of the type of fluid employed.&#xD;
&#xD;
      Data will be collected at 24 hour interval (once daily), usually during the &quot;morning&quot; shift&#xD;
      of each day of the study (between 7:00 AM and 11:00 AM, using the values closest to 9:00 AM).&#xD;
      Data will be collected from the 1st day until the 28th day of ICU admission, or until ICU&#xD;
      discharge, whichever comes first. Survival data will be collected until the 90th day after&#xD;
      randomization.&#xD;
&#xD;
      Due to the characteristics of the study population, &quot;lost to follow-up&quot; patients are expected&#xD;
      to be an exceptionally rare event, not influencing the main analyses on survival, based on&#xD;
      the standard &quot;intention to treat&quot; criteria.&#xD;
&#xD;
      MONITORING OF THE STUDY&#xD;
&#xD;
      The strategy adopted to assure a monitoring as closely as possibly compliant to the GCP&#xD;
      requirements responds to two characteristics of the study:&#xD;
&#xD;
        1. The protocol coincides with what normally required for the care of septic patients;&#xD;
&#xD;
        2. It is assumed that the criteria for the management of critically ill patients are&#xD;
           substantially respected across the large spectrum of the participating units.&#xD;
&#xD;
      The standard GCP requirements related to point a, will be assured through the monitoring role&#xD;
      of the clinical pharmacists of each center, coordinated by the Study Center of the Italian&#xD;
      Society of Hospital Pharmacists (Centro Studi SIFO), which has already a recognized tradition&#xD;
      in this area (www.sifoweb.it). The type of treatment which is the object of the study is&#xD;
      particularly suited for this choice, as by definition albumin distribution must be already&#xD;
      monitored on a per patient basis, and all the requirements related to the control of&#xD;
      compliance with the study procedures is easily integrated with the clinical monitoring&#xD;
      described above.&#xD;
&#xD;
        1. To assure and monitor the compliance with point b, the following procedures are&#xD;
           foreseen: the large network of participating centers will be divided into &quot;subgroups&quot;,&#xD;
           each including 15-20 clinical units, under the responsibility of a monitor selected by&#xD;
           the study organization with formal competences in the management of the clinical&#xD;
           conditions under study.&#xD;
&#xD;
        2. The standard GCP &quot;initiation visits&quot; will be transformed into training seminars for each&#xD;
           group, with the participation of at least 2 persons per center, including the Principal&#xD;
           Investigator (PI) of the unit (and/or his/her delegate) and a nurse in charge of the&#xD;
           operational procedures.&#xD;
&#xD;
        3. The clinical monitor will assure, specifically over the first year, at least 1 visit for&#xD;
           the centers of his/her subgroup, to review with the clinical staff how inclusion&#xD;
           criteria have been adhered to, and the targets of the background treatment strategies&#xD;
           could be respected. The clinical monitor will also assure a permanent &quot;on call&quot;&#xD;
           availability, to guarantee a correct and more efficient application of study criteria.&#xD;
&#xD;
      The coordination and management of the specific strategy illustrated above is under the joint&#xD;
      responsibility of Consorzio Mario Negri Sud and of the Centro Studi SIFO, which are not&#xD;
      involved in any of the activities related to patient selection and treatment, and have a long&#xD;
      tradition in the area of organizing and monitoring large-scale clinical trials, conducted by&#xD;
      and with not-for-profit collaborative groups.&#xD;
&#xD;
      SAMPLE SIZE ESTIMATES In Italy, ICU mortality for severe sepsis can be assumed to be about&#xD;
      45%. The objective of a 15% relative reduction of mortality, corresponding to an absolute&#xD;
      mortality reduction of 7.5%, has been chosen as a clinically relevant objective, based on&#xD;
      what observed at day 28 in the subgroup analysis of the SAFE study. The randomization of&#xD;
      ~1350 patients allows reaching this objective, with a power of 0.80, and a two-sided level of&#xD;
      significance of 0.05. As the number of participating centers appears already compatible with&#xD;
      the possibility of including a larger cohort, it is anticipated that at the occasion of the&#xD;
      second interim analysis, a specific request could be made to the Data and Safety Monitoring&#xD;
      Board (DSMB) to advise on the opportunity of targeting a sample size of ~1800 patients, which&#xD;
      is suitable to reliably assess also a lower (but still clinically relevant) absolute&#xD;
      reduction of 6.5%.&#xD;
&#xD;
      ORGANIZATIONAL CHARACTERISTICS Up to 150 ICUs (which have already a tradition of cooperative&#xD;
      studies) are expected to be able to randomize patients into the trial. A further expansion of&#xD;
      the network is foreseen, as the Italian Society of Anesthesia and Intensive Care&#xD;
      (S.I.A.A.R.T.I.), of whom the study PI is the President for the study period (2007-2010) has&#xD;
      explicitly endorsed the protocol. All ICUs of the Society could adhere to the study, provided&#xD;
      they are ready to document their logistic capability, and to be assessed and trained for the&#xD;
      specific requirements of the study.&#xD;
&#xD;
      The study is coordinated by a Steering Committee which includes the scientific&#xD;
      representatives of the Institutions assuming all the competences and organizational know-how&#xD;
      required for the trial:&#xD;
&#xD;
        1. Istituto di Anestesia e Rianimazione, Fondazione IRCCS - &quot;Ospedale Maggiore Policlinico,&#xD;
           Mangiagalli, Regina Elena&quot;, Università degli Studi di Milano [Coordinating Center]: L.&#xD;
           Gattinoni, P. Caironi&#xD;
&#xD;
        2. Dipartimento di Medicina Perioperatoria e Terapia Intensiva, Azienda Ospedaliera San&#xD;
           Gerardo di Monza, Università degli Studi Milano-Bicocca: A. Pesenti, R. Fumagalli&#xD;
&#xD;
        3. Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti: G. Tognoni, M. Romero&#xD;
&#xD;
        4. Istituto di Ricerche Farmacologiche Mario Negri, Milano: R. Latini, S. Masson&#xD;
&#xD;
      The DSMB includes two internationally well-known ICU clinicians (P.M. Suter, J.L.Vincent), an&#xD;
      independent statistician, specifically competent on survival analyses of complex&#xD;
      patients-populations (M.G. Valsecchi), one of the leading Italian figures in the area of&#xD;
      bioethical and legal requirements in medical research (A. Santosuosso).&#xD;
&#xD;
      TIMING&#xD;
&#xD;
      The calendar below provides a reasonably realistic timetable for the activities (Time 0 is&#xD;
      assumed to be the notification of the study approval):&#xD;
&#xD;
        1. 0-6 months: protocol presentation and approval by the Ethical Committees; final centers'&#xD;
           selection and investigators' training&#xD;
&#xD;
        2. 7-28 months: patient randomization&#xD;
&#xD;
        3. First interim analysis (after the first ~600 patients)&#xD;
&#xD;
        4. Second interim analysis (after 1000 patients)&#xD;
&#xD;
        5. Closure of the study (after 28 months)&#xD;
&#xD;
        6. Presentation of the final report (4 months after the database locking)&#xD;
&#xD;
      STATISTICAL ANALYSIS All the efficacy analyses will be based on the intent to treat&#xD;
      population (ITT), consisting of all randomized patients. Background and relevant baseline&#xD;
      information will be summarized for the ITT population by treatment and presented using&#xD;
      descriptive statistics. Incidence event rate will be estimated using Kaplan-Meier survival&#xD;
      curves that will be compared using logrank analysis. Additionally, treatment efficacy will be&#xD;
      assessed by multivariate analyses using Cox's regression model. Other secondary analyses will&#xD;
      include the evaluation of efficacy on all secondary end-points. The Mantel-Haenszel procedure&#xD;
      will be applied to test for the linearity of effects among subgroups; the chi-square test&#xD;
      will be applied to test for heterogeneity of effects among the subgroups. Finally, recursive&#xD;
      partitioning techniques will be applied to identify homogeneous subgroups of patients showing&#xD;
      a higher likelihood to benefit from the study intervention. Two interim analyses are planned&#xD;
      for the double scope of monitoring safety and of verifying the correctness of the assumptions&#xD;
      made for sample size estimation regarding the primary end-point event rate in relation to the&#xD;
      anticipated survival benefit. No stopping rules are foreseen, for utility or for efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality rate at the 28th day after randomization, with a further control at 90th day.</measure>
    <time_frame>mortality at 28th and 90th day after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of organ dysfunction (as recorded by the SOFA score)</measure>
    <time_frame>At 28th day after randomization and at ICU discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>ICU discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1818</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1, Albumin and Crystalloids</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2, Crystalloids</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Albumin and Crystalloids</intervention_name>
    <description>From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:&#xD;
1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:&#xD;
if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;&#xD;
if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;&#xD;
if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted.</description>
    <arm_group_label>1, Albumin and Crystalloids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Crystalloids</intervention_name>
    <description>Volume replacement will be performed in both the treated and the control group according to the &quot;early-goal directed therapy&quot;.&#xD;
control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed.</description>
    <arm_group_label>2, Crystalloids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe sepsis or septic shock, if each one of the following criteria is&#xD;
             satisfied:&#xD;
&#xD;
               -  Proved or suspected infection in at least one site:&#xD;
&#xD;
                    -  lung&#xD;
&#xD;
                    -  abdomen&#xD;
&#xD;
                    -  genito-urinary tract&#xD;
&#xD;
                    -  other (blood, skin and soft tissue, central nervous system, bones and&#xD;
                       joints, cardiac system, catheter-related infection, other)&#xD;
&#xD;
               -  Two or more of the following:&#xD;
&#xD;
                    -  a core temperature ≥ 38° C o ≤ 36° C&#xD;
&#xD;
                    -  a heart rate ≥ 90 beats/min&#xD;
&#xD;
                    -  a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of mechanical&#xD;
                       ventilation for an acute process&#xD;
&#xD;
                    -  a white blood cell count ≥ 12000/ml or ≤ 4000/ml or immature neutrophils &gt;&#xD;
                       10%&#xD;
&#xD;
               -  Presence of at least a severe organ dysfunction, as measured by the modified&#xD;
                  Sequential Organ Failure Assessment (SOFA) score:&#xD;
&#xD;
                    -  respiratory score &gt; 1&#xD;
&#xD;
                    -  hematologic score &gt; 1&#xD;
&#xD;
                    -  hepatic score &gt; 1&#xD;
&#xD;
                    -  cardiovascular score equal to 1, 3 or 4&#xD;
&#xD;
                    -  renal score &gt; 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  Terminal state&#xD;
&#xD;
          -  Known adverse reaction to albumin administration&#xD;
&#xD;
          -  Severe sepsis or septic shock in patients after proved or suspected head injury,&#xD;
             clinically active&#xD;
&#xD;
          -  Congestive heart failure (NYHA score III and IV)&#xD;
&#xD;
          -  Pathological conditions in which albumin administration is clinically indicated&#xD;
             (hepatic cirrhosis with ascites, intestinal malabsorption syndrome, nephritic&#xD;
             syndrome, burns)&#xD;
&#xD;
          -  More than 24 hours since inclusion criteria were met&#xD;
&#xD;
          -  Religious objection to the administration of human blood products&#xD;
&#xD;
          -  Inclusion in other experimental study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Gattinoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Caironi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Pesenti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dipartimento di Medicina Perioperatoria e Terapia Intensiva, Azienda Ospedaliera San Gerardo di Monza, Università degli Studi Milano-Bicocca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Fumagalli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dipartimento di Medicina Perioperatoria e Terapia Intensiva, Azienda Ospedaliera San Gerardo di Monza, Università degli Studi Milano-Bicocca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianni Tognoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Consorzio Mario Negri Sud, S. Maria Imbaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilena Romero</last_name>
    <role>Study Chair</role>
    <affiliation>Consorzio Mario Negri Sud, S. Maria Imbaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Latini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Masson</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; Via F. Sforza 35</name>
      <address>
        <city>Milano</city>
        <zip>20135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <last_update_submitted>November 7, 2015</last_update_submitted>
  <last_update_submitted_qc>November 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serum albumin, severe sepsis, septic shock, fluid therapy, hypoalbuminemia, critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

